Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Consensus Rating of "Hold" by Analysts

Key Points

• Iovance Biotherapeutics has a consensus rating of "Hold" from 15 analysts, with two sell ratings, seven holds, and six buys, and the average target price is $11.90.
• The company reported a loss of ($0.33) EPS for the last quarter, missing analyst expectations, with revenues of $59.95 million compared to expectations of $67.14 million.
• Institutional investors own 77.03% of Iovance’s stock, with several large investors significantly increasing their positions during the last quarter.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report) has earned a consensus rating of "Hold" from the fifteen analysts that are presently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have given a buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $11.90.

Several equities research analysts have weighed in on IOVA shares. HC Wainwright reiterated a "buy" rating and issued a $20.00 target price on shares of Iovance Biotherapeutics in a report on Tuesday, August 19th. Wells Fargo & Company lowered their target price on Iovance Biotherapeutics from $18.00 to $14.00 and set an "overweight" rating for the company in a report on Friday, August 8th. Zacks Research upgraded Iovance Biotherapeutics to a "hold" rating in a report on Tuesday, August 12th. The Goldman Sachs Group cut Iovance Biotherapeutics from a "neutral" rating to a "sell" rating in a report on Tuesday, July 15th. Finally, Weiss Ratings reiterated a "sell (e+)" rating on shares of Iovance Biotherapeutics in a report on Saturday, September 27th.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Osaic Holdings Inc. increased its position in Iovance Biotherapeutics by 106.7% during the 2nd quarter. Osaic Holdings Inc. now owns 88,856 shares of the biotechnology company's stock valued at $154,000 after buying an additional 45,877 shares in the last quarter. Squarepoint Ops LLC increased its position in Iovance Biotherapeutics by 115.2% during the 2nd quarter. Squarepoint Ops LLC now owns 856,569 shares of the biotechnology company's stock valued at $1,473,000 after buying an additional 458,540 shares in the last quarter. Cim Investment Management Inc. increased its position in Iovance Biotherapeutics by 100.7% during the 2nd quarter. Cim Investment Management Inc. now owns 61,117 shares of the biotechnology company's stock valued at $105,000 after buying an additional 30,671 shares in the last quarter. B. Riley Wealth Advisors Inc. acquired a new position in Iovance Biotherapeutics during the 2nd quarter valued at about $75,000. Finally, Tower Research Capital LLC TRC increased its position in Iovance Biotherapeutics by 277.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 41,723 shares of the biotechnology company's stock valued at $72,000 after buying an additional 30,668 shares in the last quarter. 77.03% of the stock is owned by institutional investors.

Iovance Biotherapeutics Stock Up 4.0%

IOVA opened at $2.34 on Friday. The business has a fifty day moving average of $2.38 and a 200 day moving average of $2.49. Iovance Biotherapeutics has a 52-week low of $1.64 and a 52-week high of $12.51. The stock has a market cap of $846.74 million, a P/E ratio of -1.90 and a beta of 0.83.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.04). Iovance Biotherapeutics had a negative net margin of 161.44% and a negative return on equity of 52.87%. The business had revenue of $59.95 million for the quarter, compared to analysts' expectations of $67.14 million. Iovance Biotherapeutics has set its FY 2025 guidance at EPS. Equities analysts anticipate that Iovance Biotherapeutics will post -1.24 EPS for the current fiscal year.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.